Publications by authors named "Timothy Harrower"

Claim this Profile
E
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
Jeremy Chataway, Thomas Williams, James Blackstone, Nevin John, Marie Braisher, Timothy Harrower

Lancet· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.
James Blackstone, Thomas Williams, Jennifer M Nicholas, Ekaterina Bordea, Floriana De Angelis, Timothy Harrower

BMJ Open· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dyspnea (breathlessness) in amyotrophic lateral sclerosis/motor neuron disease: prevalence, progression, severity, and correlates.
Carolyn A Young, Amina Chaouch, Christopher J Mcdermott, Ammar Al-Chalabi, Suresh K Chhetri, Timothy Harrower

Amyotroph Lateral Scler Frontotemporal Degener· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlates and trajectories of relapses in relapsing-remitting multiple sclerosis.
Carolyn A Young, David J Rog, Basil Sharrack, Radu Tanasescu, Seema Kalra, Timothy Harrower

Neurol Sci· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring disability in amyotrophic lateral sclerosis/motor neuron disease: the WHODAS 2.0-36, WHODAS 2.0-32, and WHODAS 2.0-12.
Carolyn A Young, John Ealing, Christopher J McDermott, Tim L Williams, Ammar Al-Chalabi, Timothy Harrower

Amyotroph Lateral Scler Frontotemporal Degener· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of smoking cessation on multiple sclerosis disease progression.
Jeff Rodgers, Tim Friede, Frederick W Vonberg, Cris S Constantinescu, Alasdair Coles, Timothy Harrower

Brain· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy.
Carolyn A Young, Roger Mills, David Rog, Basil Sharrack, Tahir Majeed, Timothy Harrower

J Neurol Sci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment.
Simeng Lin, Harry D Green, Peter Hendy, Neel M Heerasing, Neil Chanchlani, Timothy Harrower

J Crohns Colitis· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring quality of life in ALS/MND: validation of the WHOQOL-BREF.
Carolyn A Young, Roger Mills, Ammar Al-Chalabi, Georgina Burke, Siddharthan Chandran, Timothy Harrower

Amyotroph Lateral Scler Frontotemporal Degener· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health state utility values (QALY weights) for Huntington's disease: an analysis of data from the European Huntington's Disease Network (EHDN).
Annie Hawton, Colin Green, Elizabeth Goodwin, Timothy Harrower

Eur J Health Econ· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease.
Carolyn Anne Young, John Ealing, Christopher McDermott, Tim Williams, Ammar Al-Chalabi, Timothy Harrower

Amyotroph Lateral Scler Frontotemporal Degener· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2).
Belinda Lennox, Ksenija Yeeles, Peter B Jones, Michael Zandi, Eileen Joyce, Timothy Harrower

Trials· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of cell suspension allografts in a patient with Huntington's disease.
Alexander Maxan, Sarah Mason, Martine Saint-Pierre, Emma Smith, Aileen Ho, Timothy Harrower

Ann Neurol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom.
Madhusubramanian Muthukumar, Kamal Desai, Seye Abogunrin, Timothy Harrower, Sylvie Gabriel

Clinicoecon Outcomes Res· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis.
Alexander J McGeachan, Esther V Hobson, Ammar Al-Chalabi, Jodie Stephenson, Siddharthan Chandran, Timothy Harrower

Amyotroph Lateral Scler Frontotemporal Degener· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis.
Seye Abogunrin, Sarah Brand, Kamal Desai, Jerome Dinet, Sylvie Gabriel, Timothy Harrower

Clinicoecon Outcomes Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of sialorrhoea in motor neuron disease: a survey of current UK practice.
Esther V Hobson, Alexander McGeachan, Ammar Al-Chalabi, Siddharthan Chandran, Francesca Crawley, Timothy Harrower

Amyotroph Lateral Scler Frontotemporal Degener· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

Nat Genet· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease.
Roger A Barker, Sarah L Mason, Timothy P Harrower, Rachel A Swain, Aileen K Ho

J Neurol Neurosurg Psychiatry· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TB or not TB?
Timothy Harrower, Dominic O'Donovan, Sebastiano Bavetta, Abhijit Chaudhuri

Am J Med· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stent placement for management of a small parasagittal meningioma. Technical note.
Dharmendra Ganesan, J Nicholas P Higgins, Timothy Harrower, Neil G Burnet, Nicholas J C Sarkies

J Neurosurg· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
POLG1 mutations manifesting as autosomal recessive axonal Charcot-Marie-Tooth disease.
Timothy Harrower, Joanna D Stewart, Gavin Hudson, Henry Houlden, Graham Warner

Arch Neurol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lewy bodies in Parkinson's disease: protectors or perpetrators?
Timothy P Harrower, Andrew W Michell, Roger A Barker

Exp Neurol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell therapies for neurological disease--from bench to clinic to bench.
Timothy Harrower, Roger A Barker

Expert Opin Biol Ther· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is there a future for neural transplantation?
Timothy P Harrower, Roger A Barker

BioDrugs· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis